Epigral Limited — Updates, 02-08-2025: Press Release

Epigral's Q1FY26 revenue decreased 6% to ₹615 Cr. PAT rose to ₹160 Cr, significantly boosted by an ₹81 Cr deferred tax gain; core PAT was ₹79 Cr. EBITDA margin held strong at 27% despite lower volumes. Plant utilization was 73%. ROCE improved to 24%, and Net Debt/EBITDA significantly reduced to 0.6x. Derivatives & Specialty business contributes 50% of revenue and is expected to grow. Management anticipates a stronger H2FY26. Capex projects for CPVC and Epichlorohydrin expansion are on schedule, with plans for new import substitution chemistry.